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SwitzerlandA B S T R A C TObjective: Several characteristics of bone-targeted agents are consid-
ered when making treatment decisions. This study evaluated physi-
cians’ therapy preferences for preventing skeletal-related events
(SREs) in patients with bone metastases secondary to solid tumors.
Methods: A Web-enabled, discrete-choice experiment online survey
was conducted among physicians who treated patients with bone
metastases and solid tumors in the United States. Respondents chose
between pairs of hypothetical medications deﬁned by combinations of
six attributes at varying levels for two hypothetical patients. Prefer-
ence weights for attribute levels were estimated using a random-
parameters logit model. Results: In total, 200 physicians completed
the survey. Their mean age was 52 years, 57% were in practice for more
than 15 years, 37% were oncologists, and 65% treated 10 or fewer
patients with bone metastases weekly. Out-of-pocket cost to patients
was the most important attribute overall. Among clinical outcomes,
time to ﬁrst SRE and risk of renal impairment were the most important
attributes. Statistically signiﬁcant preferences were observed for all
attribute levels for time to ﬁrst SRE, risk of renal impairment, and modeee front matter & 2015 Published by Elsevier Inc.
(ISPOR). This is an open access article under the
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ndence to: Yi Qian, One Amgen Center Drive, M/Sof administration. Predicted choice probability analysis showed that
physicians preferred a hypothetical medication with attributes similar
to those of denosumab over one with attributes similar to those of
zoledronic acid. Conclusions: Physicians indicated that clinical attrib-
utes are important when considering bone-targeting therapy for bone
metastases, but consistent with the current health care landscape,
patient out-of-pocket cost was the most important. With health care
costs being increasingly shifted to patients, physicians require accurate
information about co-pays and assistance programs to avoid patients
receiving less costly, yet potentially inferior, treatment.
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Bone is the most common site for metastasis in cancer, especially
in breast and prostate cancers [1]. Approximately 70% of patients
with metastatic breast or prostate cancer will develop bone
metastases [1–4]. Bone metastases are also common in patients
with advanced lung, kidney, or thyroid cancer, with an estimated
incidence of 30% to 40% observed postmortem [1,5,6]. The
prevalence of metastatic bone disease across all cancer types in
the US adult population is estimated to be 280,000 cases,
although this number is likely an underestimate because of
underdiagnosis and underreporting of cases in claims data [7].
Skeletal-related events (SREs), deﬁned as pathologic fractures,
spinal cord compression, and surgery or radiation to bone, areserious skeletal complications that occur frequently in patients
with bone metastases [2,8]. Although the term SRE refers to a
combination of spontaneous medical events (spinal cord com-
pression or pathologic fracture) or a clinically signiﬁcant
unplanned medical procedure (radiation to bone or surgery to
bone) that is initiated in response to severe pain or imminent/
actual pathologic fracture, both are associated with signiﬁcant
humanistic and economic burden to the patient and the health
care system. SREs are debilitating and may lead to pain and
impaired mobility, and thus, reduced health-related quality of
life, as well as increased mortality [1,6]. Health care costs
associated with SREs are considerable [9–11], with average med-
ical costs of $54,751 and $11,768 (2010 US dollars) for managing
each inpatient and outpatient SRE episode, respectively [12].on behalf of International Society for Pharmacoeconomics and
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Table 1 – Attributes and levels for the choice
questions.
Attribute Levels
Time until ﬁrst SRE 28 mo
18 mo
10 mo
Time until a 2-point increase in pain on the
BPI-SF (time until worsening of pain)
10 mo
6 mo
3 mo
Risk of ONJ each year None
1 out of 100 (1%)
5 out of 100 (5%)
Risk of 0.5-mg/dL increase in baseline
creatinine each year (risk of renal
impairment)
None
4 out of 100 (4%)
10 out of 100 (10%)
Mode of administration and frequency Injection every 4
wk
15-min infusion
every 4 wk
120-min infusion
every 4 wk
Out-of-pocket cost to the patient each
month ($)
25
75
150
330
BPI-SF, Brief Pain Inventory Short Form; ONJ, osteonecrosis of the
jaw; SRE, skeletal-related event.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 7 8 – 8 3 79Before the availability of denosumab, drug therapy options for
bone metastasis in the United States were limited to bisphosph-
onates, predominantly zoledronic acid. In 2010, denosumab was
approved by the US Food and Drug Administration for the
prevention of SREs in patients with bone metastases associated
with solid tumors on the basis of its superiority to zoledronic acid
in delaying the ﬁrst onset of SREs (median 8.21 months) in three
randomized controlled trials [13]. Nonetheless, treatment deci-
sions may not solely depend on the efﬁcacy proﬁle of a drug
therapy; factors such as the safety proﬁle (e.g., adverse events),
mode of drug administration (e.g., intravenous vs. subcutaneous
route), and out-of-pocket costs to patients may also play an
important role. In addition to the superior efﬁcacy of denosumab
over zoledronic acid, the attributes that may inﬂuence decisions
are different between the two options [14–17].
Physician preferences for pharmacologic therapy to prevent or
delay SREs in cancer patients with bone metastases have not
been assessed. The primary objective of this study was to assess
and quantify these preferences in the US setting.
To achieve this, we used a discrete-choice experiment (DCE) to
assess the medication preferences of physicians in the United
States. DCEs have increasingly been used in medicine [18,19] and
are grounded in both psychology [20] and economics [21]. DCEs
offer a systematic method of eliciting trade-offs to quantify the
relative importance physicians, other health care decision mak-
ers, or patients place on various treatment characteristics or
treatment-related outcomes [19]. This approach is based on the
premise that treatments comprise a set of outcomes or treatment
features or attributes (e.g., efﬁcacy, adverse events, and mode of
administration) and that the relative value of a treatment to an
individual is a function of these attributes. The investigators in
this study followed best practices [22] in designing and adminis-
tering a DCE (also known as a choice-format conjoint-analysis
survey) to elicit physician preferences for a pharmacologic
therapy for the prevention of SREs in patients with bone meta-
stases secondary to a solid tumor.Methods
Survey Instrument
Six attributes of currently available medications for the preven-
tion of SREs in patients with bone metastases were identiﬁed for
evaluation and were based on the US product label information,
scientiﬁc literature, clinical trial results, and consultation with
clinical experts (Table 1) [14,15,23]. SRE was deﬁned as skeletal
complications including pathologic fracture, radiation or surgery
to bone, or spinal cord compression. The risk of osteonecrosis of the
jaw was deﬁned as the annual risk for developing an exposed
area of the jawbone for at least 8 weeks. The risk of renal impair-
ment was deﬁned as the annual risk of a 0.5-mg/dL increase in
baseline serum creatinine level. Attribute levels were designed to
encompass the ranges commonly observed in current clinical
practices as well as the ranges over which physicians are willing
to accept trade-offs among attributes. The levels for the cost
attribute were determined to span the range of likely out-of-
pocket costs that patients in the United States might incur.
Survey validation included open-ended interviews with eight
physicians in Philadelphia, PA. These interviews were conducted
(either in person or by phone) to 1) test the clarity of the survey
instrument and the appropriateness of the descriptive informa-
tion; 2) conﬁrm that the six attributes included in the survey were
salient to physicians; 3) conﬁrm that no other salient attributes
were missing; and 4) assess physicians’ willingness to accept
trade-offs among attributes in evaluating hypothetical drug
therapies. The attributes for the survey questions were presentedin an order that reﬂected the product labeling and the order in
which a physician might normally communicate to patients.
To create drug therapy proﬁle pairs for the choice questions,
an established algorithm was used to construct a main-effects
experimental design maximizing D-efﬁciency using SAS (version
9.3; Cary, NC). The ﬁnal design included four survey versions,
each with 9 choice questions (36 choice questions in total), with
the order of the questions randomized within survey versions.
One of the questions shown was repeated as the third, seventh,
eighth, or ninth choice question. Respondents answered 10
choice questions between pairs of hypothetical drug proﬁles
(Fig. 1), making prescribing decisions in each question for one
of two hypothetical patient proﬁles (Table 2). Respondents were
randomly assigned to one of four survey versions.
Patient Proﬁles
Patient proﬁles were based on one of two hypothetical proﬁles
(Table 2). These proﬁles were evaluated during the pretest phase
with physicians, who reported that the proﬁles were representa-
tive of patients in their practices. Physicians saw both proﬁles at
the beginning of the survey. Proﬁles 1 and 2 were presented in
odd- (1, 3, 5, 7) and even-numbered (2, 4, 6, 8) questions, with the
full proﬁles presented in questions 1 and 2 and an abridged
version presented for questions 3, 5, and 7 and 4, 6, and 8,
respectively. In questions presenting the abridged version of the
patient proﬁle, the respondent could click on a hyperlink to
reveal the full description of the patient.
Study Sample
Practicing, board-certiﬁed physicians who were currently
involved in treating patients with bone metastases from a solid
tumor were eligible. A survey research company recruited mem-
bers from existing online physician panels and administered the
Fig. 1 – Example of choice questions. BPI-SF, Brief Pain Inventory Short Form; ONJ, osteonecrosis of the jaw; SRE, skeletal-
related event.
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erations were reviewed by the Ofﬁce of Research Protection and
Ethics at the responsible study organization (RTI International;
Research Triangle Park, NC). Upon recruitment, physician
respondents provided online informed consent. Demographic
information for the respondents was collected. Respondents were
excluded if there was no variation in responses to choice ques-
tions (i.e., responder chose the same option for all 10 questions)
because this was considered to indicate lack of attention to the
questions.
Statistical Analysis
Descriptive statistics, including respondents’ demographic char-
acteristics and clinical experiences, were reported. A random-
parameters logit model [24,25] was used to analyze the pattern of
physicians’ choices. Such a model relates the selection of a proﬁle
to differences in attribute levels between hypothetical treatment
alternatives. The model results reﬂect the effect of attribute
levels on the likelihood that a treatment is selected. Thus,
random-parameters logit estimates are considered mean prefer-
ence weights for attribute levels. Each preference weight indi-
cates the relative strength of preference for an attribute level—
more preferred outcomes have higher preference weights.
All attribute levels were modeled as categorical variables
using effects coding [24,25]. The 95% conﬁdence intervals of the
estimates were calculated for each preference weight. Statisti-
cally signiﬁcant differences between weights for attribute levels
were tested using a Wald test. Differences in preference-weight
estimates for levels in an attribute indicate the importance of
changing a treatment attribute from one level to the other. The
difference between the most and least important levels of anattribute indicates the overall relative importance of the range of
levels in the attribute. Estimated preference weights were also
used to calculate predicted choice probabilities for drug therapy
proﬁles. Predicted choice probabilities were calculated by adding
the preference weights for the attribute levels in each of several
available treatments to determine the proportion of physicians
who would select each proﬁle [26]. Differences in preferences for
each attribute were calculated as the denosumab value times the
preference weight minus the zoledronic acid value times the
preference weight.
A post hoc analysis was performed to determine any differ-
ences in preferences for attribute levels between oncologists and
all other specialties combined. The statistical signiﬁcance of all
estimated differences was jointly tested using a Wald test. All
statistical analyses were conducted using NLOGIT 4.0 (Economet-
ric Software, Inc., Plainview, NY).Results
Response Rate
A total of 5020 US physicians were invited to participate in the
survey. Of those invited, 341 individuals (7%) responded to the
invitation and, of those who responded, 260 (76%) were eligible to
participate (i.e., those physicians who were practicing, board-
certiﬁed, and currently treating patients with bone metastases
from solid tumors). A total of 256 of 260 (98%) eligible physicians
consented to participate and 200 (78%) completed the survey.
Data for all 200 physicians were included in the ﬁnal analysis.
Table 3 – Demographic characteristics for
respondents.
Category Physicians
(N ¼ 200)
Age (y), mean  SD 51.9 (10.4)
No. of years in practice (%)
1–9 36 (18)
10–20 88 (44)
420 76 (38)
Type of practice, n (%)
Ofﬁce-based private practice 142 (71.0)
Hospital-based private practice 30 (15.0)
Academic hospital-based practice 44 (22.0)
Other 3 (1.5)
Area of specialty, n (%)
Primary care 25 (12.6)
Family medicine 1 (0.5)
Oncology 74 (37.4)
Other 98 (49.5)
Missing 2 (1)
No. of patients with bone metastases from solid
tumors treated each week (%)
r5 78 (39)
6–10 52 (26)
410 70 (35)
Use of the BPI-SF to assess pain level in patients
with bone metastases, n (%)
All patients 30 (15.0)
Most patients 55 (27.5)
A few patients 33 (16.5)
Do not use 82 (41.0)
BPI-SF, Brief Pain Inventory Short Form.
Table 2 – Patient proﬁles.
Proﬁle Description
Patient
proﬁle 1
A 57-y-old woman who was diagnosed with
breast cancer and developed bone metastases
along with 2-cm mediastinal and
supraclavicular adenopathy 3 y after her initial
diagnosis. She initially received TC adjuvant
chemotherapy. The tumor was ER/PR positive
and HER2 negative. She was on an adjuvant
aromatase inhibitor at the time of her relapse.
Her recurrence was noted by examination
identifying the supraclavicular adenopathy. On
further questioning she admits to increasing
midback (thoracic area) pain, which she rates as
a 4 on a scale of 0–10. The patient’s health is
otherwise good (high performance status) with
no history of kidney disease and no signiﬁcant
comorbidities.
Patient
proﬁle 2
A 71-y-old man who was initially diagnosed with
Gleason 8-10 prostate cancer 3 y ago. He is now
castration resistant and has developed bone
metastases. His PSA level is Z10. He is
complaining of left hip pain when he walks and
low back pain if he sits too long, which he rates
as a 4 on a scale from 0 to 10. The patient’s
health is otherwise good (high performance
status), with no history of kidney disease and
no signiﬁcant comorbidities.
ER/PR, estrogen receptor/progesterone receptor; HER2, human
epidermal growth receptor 2; PSA, prostate-speciﬁc antigen; TC,
docetaxel/cyclophosphamide.
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Demographic characteristics for the 200 respondents are presented
in Table 3. The mean age of physicians in the sample was 51.9
years. Physicians were board-certiﬁed in 44 different states, with 69
(34.5%) of them certiﬁed in states in the northeastern region, 33
(16.6%) in the midwest region, 66 (33.0%) in the southern region,
and 32 (16.0%) in the western region of the United States. Most
(82.0%) physicians had been in practice for more than 10 years
since completing their medical training, and more than half (56.5%)
had been in practice for longer than 15 years. Most of the
physicians (71.0%) indicated that they were in an ofﬁce-based
private practice. The most frequently noted areas of specialization
were oncology (37.4%) and primary care (12.6%); nearly half (49.5%)
of the physicians described their specialty as “other.” All physicians
treated patients with bone metastases from solid tumors, typically
up to 10 patients each week (65.0%). The Brief Pain Inventory Short
Form was used in their practice for all patients by 15.0% of the
physicians and for most patients by 27.5% of the physicians.
Preference Weights
The preference weights for the six attributes (time until ﬁrst SRE,
time until 2-point increase in pain on the Brief Pain Inventory
Short Form, risk of osteonecrosis of the jaw each year, risk of 0.5-
mg/dL increase in baseline creatinine level each year [risk of renal
impairment], mode of administration, and out-of-pocket cost to
patient each month) included in the analysis from Table 1 are
presented in Figure 2. The parameter estimates can be interpreted
as the relative strength of preference for each attribute level [22].
As seen in Figure 2, the most important attributes were out-of-
pocket expenses, time until ﬁrst SRE, and risk of renal impairment.
The mean estimates were ordered as expected for time until ﬁrstSRE and risk of renal impairment, with better clinical outcomes
having higher estimates; the mean estimates were statistically
signiﬁcantly different between all adjacent levels (P o 0.05). Mean
estimates were ordered as expected for time until worsening of
pain, risk of osteonecrosis of the jaw, and out-of-pocket cost, but
the ﬁrst two adjacent levels were not statistically signiﬁcantly
different (P 4 0.05). The mode of administration does not have a
natural ordering, but an injection every 4 weeks was signiﬁcantly
preferred over a 15-minute infusion every 4 weeks (Po 0.05), and a
15-minute infusion every 4 weeks was signiﬁcantly preferred over
a 120-minute infusion every 4 weeks (P o 0.05).
For each attribute level, the difference in preferences between
oncologists and all other physicians was estimated in a post hoc
analysis. The null hypothesis for the test was that all estimated
differences were zero. The estimated P value for the Wald test
was 0.2982, suggesting that there is no difference between
oncologists’ preferences and preferences of other physicians in
the study. With respect to the hypothetical patient proﬁles, no
statistically signiﬁcant differences in physician treatment pref-
erences were observed between responders with full access to
either patient proﬁle.Predicted Choice Probabilities
The proﬁles of attributes for denosumab and zoledronic acid were
derived from the prescribing information and clinical trial data
for these products [14,15,23] and are summarized in Table 4. Data
for the predicted choice probabilities in terms of the percentages
that one alternative with its associated attributes would be
chosen over the other are also presented in Table 4. Physicians
were not directly asked about their preference for existing
Fig 2 – Preference-weight graph. The vertical bars surrounding each mean preference weight denote the 95% CI about the
point estimate. If the CIs do not overlap for adjacent levels in a particular attribute, the mean estimates are statistically
different from each other at the 5% level of signiﬁcance. BPI-SF, Brief Pain Inventory Short Form; CI, conﬁdence interval; ONJ,
osteonecrosis of the jaw; SRE, skeletal-related event.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 7 8 – 8 382treatments, but on the basis of preference estimates from the
survey results, physicians preferred a drug therapy with attrib-
utes similar to those of denosumab (98.4%; 95% conﬁdence
interval, 95.6%–99.5%) over a drug therapy with attributes similar
to those of zoledronic acid (1.6%; 95% conﬁdence interval, 0.6%–
4.4%). The major clinical contributors inﬂuencing the choice
between the two drugs were risk of renal impairment and the
occurrence of SREs. This is observed by the difference in prefer-
ence between denosumab and zoledronic acid for each attributeTable 4 – Predicted Choice Probabilities.
Attribute Characteristics Similar to
Denosumab
Characte
Zoledron
Proﬁles*
Time until ﬁrst SRE,
mo
27.7
Time until worsening
of pain, mo
6.6
Risk of ONJ, % 1.8
Risk of renal
impairment, %
0
Mode of
administration
Injection every 4 weeks 15-min in
Predicted choice
probabilities†
98.4% (95.6%–99.5%) 1.
NA, not applicable; ONJ, osteonecrosis of the jaw; SRE, skeletal-related e
* Values derived from prescribing information for denosumab[14] and zo
† Values represent the predicted probability (95% CI) that each alternat
represented the only available treatment options.(Table 4), which was 2.20 for renal impairment (favoring deno-
sumab) and 1.05 for time until ﬁrst SRE (favoring denosumab).Discussion
The results of this DCE analysis showed that given the range of
levels included, physicians consider out-of-pockets costs to
patients, time until the ﬁrst SRE, and risk of renal impairmentristics Similar to
ic Acid
Preference Difference (Denosumab–
Zoledronic Acid)
19.5 1.05
4.7 0.32
1.3 –0.14
9.3 2.20
fusion every 4 weeks 0.68
6% (0.6%–4.4%) NA
vent.
ledronic acid [15].
ive with its associated attributes would be chosen if these proﬁles
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therapy for the prevention of SREs in patients with bone meta-
stases due to solid tumors. Given that out-of-pocket costs are the
most important attribute in this analysis, it seems that physi-
cians understand that such costs, which vary in the United States
by health plan and coverage, are an important factor for patients,
and indeed, studies have conﬁrmed that this is of relatively equal
importance for both physicians and patients [27]. These observa-
tions underscore the importance of increasing awareness of
health plan coverage and patient support programs to enable
caregivers to present a more comprehensive view of available
treatment options for bone metastases, facilitating a joint treat-
ment decision between physicians and patients.
The predicted choice probabilities derived from these results
demonstrated that physicians preferred a hypothetical pharma-
cologic therapy with attributes similar to those of denosumab
over a hypothetical pharmacologic therapy with attributes similar
to those of zoledronic acid. This study was speciﬁcally designed to
isolate preferences for therapeutic choices from perceptions based
on marketing and preconceptions of currently available therapies.
A number of study limitations need to be considered.
Respondents were asked to make simulated clinical decisions
on hypothetical drug therapies, which have hypothetical rather
than actual consequences. We have attempted to minimize this
bias by making the hypothetical choices mimic real-world trade-
offs as closely as possible and by verifying the survey attributes
with open-ended interviews during survey testing. The response
rate for this study was low (o10%), and data on the character-
istics of nonrespondents are not known (i.e., those who did not
meet the inclusion criteria or who did not consent to participate).
Thus, the recruitment procedure used in this study may have
resulted in selection bias. In addition, only 37% of the respond-
ents were oncologists, who are most likely to manage patient
treatment for bone metastases from solid tumors, and nearly 50%
of the respondents indicated “other” as their specialty. A post hoc
analysis, however, showed that results were similar for oncolo-
gists versus nononcologists (all the remaining physicians in the
study), although the study was not designed to detect the differ-
ence between subgroups of respondents. Payment by the health
care insurer was not included as a question because the purpose
of the study was to evaluate the preference for a medication on
the basis of attributes that directly affect the patient. Moreover,
this study did not investigate whether physicians have reliable
tools to determine out-of-pocket costs for an individual patient.
To our knowledge, this is the ﬁrst discrete-choice study to
evaluate physicians’ preferences for drug therapies for bone meta-
stases secondary to solid tumors. Bone-targeted therapy is needed
in patients with bone metastases to delay or prevent SREs and to
maintain or improve patients’ quality of life. Determining physi-
cians’ preferences for pharmacologic therapy helps understand their
decision-making process when considering multiple treatment
options and highlights the physicians’ priorities regarding the treat-
ment attributes. This, in turn, should aid other physicians’ decisions
about patient management and, in this situation, improve the
management of bone metastases when available alternatives exist.Acknowledgments
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